SITC23 Posters with Oral Presentation recording by Alloplex Biotherapeutics Inc’s Founder and Chief Executive Officer, Dr. Frank Borriello.

June 12, 2024. 

SITC 2023, Poster 381, with Audio Commentary by Dr. Borriello

SUPLEXA, a multimodal autologous cellular therapy, shows immunomodulatory behavior in cancer patients consistent with improved anti-tumor immune function.

Authors: J Pulford, E Murzin, D Younger, R Joshi, JC Goh, G Kichenadasse, SE Gargosky, F Borriello, and J Lederer.  


SITC 2023, Poster 727, with Audio Commentary by Dr. Borriello

Topline safety and efficacy update of SUPLEXA-101, a First-in-Human, Single Agent Study of SUPLEXA Therapeutic Cells in 28 Patients with Metastatic Solid Tumors.

Authors: R Joshi, JC Goh, G Kichenadasse, V Atkinson, W Joubert, V Kwatra, M Okera, S Bishnoi, G Nisyrios, J Lederer, SE.